What do the experts have to say? Take a moment to review these short videos featuring IC experts from around the country.

KOL Video: Start with ELMIRON®

With:
David M. Kaufman, MD
Assistant Professor of Clinical Urology,
Columbia University
Central Park Urology
New York, NY

Ortho Women's Health & Urology™ Consultant Speaker



KOL Video: Stay with ELMIRON®

With:
David M. Kaufman, MD
Assistant Professor of Clinical Urology,
Columbia University
Central Park Urology
New York, NY

Ortho Women's Health & Urology™ Consultant Speaker



IC Cast: Interstitial Cystitis (IC) or Overactive Bladder (OAB)?

With:
Robert J. Evans, MD
Associate Professor of Urology
Wake Forest University
Scott A. MacDiarmid, MD
Alliance Urology Specialists
Greensboro, NC
Clinical Faculty, Department of Urology
Wake Forest University




Ortho Women's Health & Urology™ Consultant Speaker




Important Safety Information

  • Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients
  • Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage
  • Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp
  • Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug
  • Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%)